npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers557
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer270
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer178
Biological correlates associated with high-risk breast cancer patients identified using a computational method125
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients102
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer100
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer98
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab97
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–202194
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells87
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination81
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab79
Immunotherapy for early triple negative breast cancer: research agenda for the next decade74
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer66
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment65
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer60
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors59
International survey on invasive lobular breast cancer identifies priority research questions59
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial58
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC56
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)54
Breastfeeding attributable fraction of triple negative breast cancer in the US54
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice53
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer53
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer47
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events43
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays43
Temporal evolution of breast cancer brain metastases treatments and outcomes43
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models42
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases41
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions39
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study37
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer36
Survival outcomes after omission of surgery for ductal carcinoma in situ36
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines35
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer35
Circulating tumor DNA validity and potential uses in metastatic breast cancer35
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer34
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment33
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer33
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer33
Is conservative management of ductal carcinoma in situ risky?31
Understanding metastasis mixed-treatment responses through genomic analyses31
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification31
Kataegis in clinical and molecular subgroups of primary breast cancer30
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer30
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center30
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models30
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature30
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries29
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer28
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment27
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies27
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin27
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201626
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program25
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer25
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer25
Large language model (ChatGPT) as a support tool for breast tumor board24
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance24
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer24
A systematic review of determinants of breast cancer risk among women with benign breast disease23
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy23
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer23
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab23
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 23
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Cook and Move for Your Life, an eHealth intervention for women with breast cancer22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies22
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study22
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer21
Prognostic value of structural variants in early breast cancer patients21
Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer20
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis20
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape19
SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning19
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women19
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer19
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study19
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer19
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women19
Author Correction: Advancing equitable access to innovation in breast cancer19
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention18
Proteogenomic characterization of invasive breast tumors in young women18
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry18
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Plasma C-peptide mammographic features and risk of breast cancer18
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study17
Racial discrimination among women seeking breast cancer care17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer16
Genomic landscape of breast cancer in elderly patients16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer16
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases16
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer16
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Advancing equitable access to innovation in breast cancer15
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer15
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Artificial intelligence in breast pathology – dawn of a new era15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
0.34521698951721